Bricanyl 500micrograms/dose Turbohaler

Страна: Велика Британія

мова: англійська

Джерело: MHRA (Medicines & Healthcare Products Regulatory Agency)

Активний інгредієнт:

Terbutaline sulfate

Доступна з:

AstraZeneca UK Ltd

Код атс:

R03AC03

ІПН (Міжнародна Ім'я):

Terbutaline sulfate

Дозування:

500microgram/1dose

Фармацевтична форма:

Inhalation powder

Адміністрація маршрут:

Inhalation

Клас:

No Controlled Drug Status

Тип рецепту:

Valid as a prescribable product

Огляд продуктів:

BNF: 03010101; GTIN: 5014162007901 5000456028837

інформаційний буклет

PACKAGE LEAFLET: INFORMATION FOR THE USER
BRICANYL
 TURBOHALER
® 0.5 MG/DOSE
terbutaline sulfate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Bricanyl Turbohaler is and what it is used for
2. What you need to know before you use Bricanyl Turbohaler
3. How to use Bricanyl Turbohaler
4. Possible side effects
5. How to store Bricanyl Turbohaler
6. Contents of the pack and other information
1.
WHAT BRICANYL TURBOHALER IS AND WHAT IT IS USED FOR
Bricanyl Turbohaler is an inhaler. It contains a medicine called
terbutaline. This belongs to a
group of medicines called ‘beta-agonists’. These work by relaxing
certain muscles and
opening up the airways in the lungs.
Bricanyl Turbohaler is used for asthma and other breathing problems
where you have a tight
chest and difficulty breathing.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE BRICANYL TURBOHALER
DO NOT USE BRICANYL TURBOHALER:
•
If you are allergic to terbutaline.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before using Bricanyl Turbohaler if:
•
You have diabetes. If so, you may need some extra blood sugar tests
when you start using
Bricanyl Turbohaler.
•
You have a history of heart disease, irregular heart rhythm or angina.
•
You have an overactive thyroid gland.
If you are not sure if any of the above apply to you, talk to your
doctor or pharmacist before
using Bricanyl Turbohaler.
OTHER MEDICINES AND BRICANYL TURBOHALER
Tell your doctor or pharmacist if you are taking, have recently taken
or might take any other

Характеристики продукта

OBJECT 1
BRICANYL TURBOHALER, 0.5MG/DOSE, INHALATION
POWDER
Summary of Product Characteristics Updated 17-Nov-2015 | AstraZeneca
UK Limited
1. Name of the medicinal product
Bricanyl
®
Turbohaler
®
, 0.5mg/dose, inhalation powder
2. Qualitative and quantitative composition
Terbutaline Sulfate 0.5mg/dose.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Inhalation powder.
Breath-actuated metered dose powder inhaler.
4. Clinical particulars
4.1 Therapeutic indications
Terbutaline is a selective beta
2
-adrenergic agonist recommended for the relief and prevention of
bronchospasm in bronchial asthma and other bronchopulmonary disorders
in which bronchospasm or
reversible airways obstruction is a complicating factor.
4.2 Posology and method of administration
Posology
Adults and Children: One inhalation (0.5mg) as required. Not more than
4 inhalations should be required
in any 24-hour period.
The duration of action of a single dose is up to 6 hours.
Older people: Dosage as for adults.
Method of administration
Instructions for use and cleaning are provided in the Patient
Information Leaflet, which can be found in
each pack.
4.3 Contraindications
Hypersensitivity to the active substance.
4.4 Special warnings and precautions for use
Patients should be instructed in proper use and their inhalation
technique checked regularly.
With each inhalation a fraction of the delivered dose will be
deposited in the oral cavity. To minimize
unnecessary systemic exposure to terbutaline, the patients should be
advised to, when possible, rinse their
mouth after each use.
If a previously effective dosage regimen no longer gives the same
symptomatic relief, the patient should
urgently seek further medical advice. Consideration should be given to
the requirements for additional
therapy (including increased dosages of anti-inflammatory medication).
Severe exacerbations of asthma
should be treated as an emergency in the usual manner.
As for all beta
2
-agonists caution should be observed in patients with thyrotoxicosis